Study Summary
This trial tests a new immunotherapy treatment for pancreatic cancer patients to see if it's safe and effective. Patients receive 3 separate treatments and will be compared to an observational group.
- Pancreatic Cancer
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: Throughout the study, on average 2.4 years
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
4 Treatment Groups
Cohort C Observational
1 of 4
Cohort A
1 of 4
Cohort B
1 of 4
Cohort C Treatment
1 of 4
Active Control
Experimental Treatment
85 Total Participants · 4 Treatment Groups
Primary Treatment: Cohort A · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What is the highest recorded enrolment of patients taking part in this trial?
"Affirmative, the details from clinicaltrials.gov verify that this trial is presently welcoming participants. It was initially made public on March 13th 2023 and has since undergone its most recent update on May 4th 2023. The research requires 85 people to enrol at 1 site." - Anonymous Online Contributor
Is there still a possibility to join this research project?
"Affirmative, the public information on clinicaltrials.gov states that this research project is recruiting participants at present. This trial was originally posted online in March 13th 2023 and last updated in May 4th 2023. The experiment requires 85 patients from one medical facility to take part." - Anonymous Online Contributor
Does Cohort A have the necessary regulatory clearance to be introduced into marketplaces?
"Our team has assigned Cohort A a safety score of 1, as it is currently in the preliminary stages of its clinical trials with limited evidence to back up efficacy and safety." - Anonymous Online Contributor